SEED (7743) Fundamentals 2026 — P/E 13.8x, Revenue Analysis | SniperIQ
SEED (7743) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥15.7B, trading at ¥518.00 on the JPX. This SniperIQ fundamentals page covers SEED's valuation (P/E 13.8x, P/B 0.8x), profitability (net margin 3.3%), revenue (¥33.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SEED's market cap?
SEED (7743) has a market capitalization of approximately ¥15.7B, trading at ¥518.00 on the JPX. Market cap moves with the live share price.
What is SEED's P/E ratio?
SEED's trailing twelve-month P/E ratio is 13.8x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SEED?
SEED runs a net profit margin of 3.3%, a gross margin of 44.8%, and an operating margin of 4.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SEED generate?
SEED reported revenue of ¥33.9B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 37.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SEED pay a dividend?
SEED offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is SEED financially healthy?
SEED carries a debt-to-equity ratio of 1.48x and a current ratio of 0.79x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SEED a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SEED (7743) the key facts are: market cap ¥15.7B, P/E 13.8x, revenue ¥33.9B, 52-week range 468-659. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SEED's full fundamentals live
Get SEED's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.